4,5-二氟-2-甲氧基苄胺 | 886497-93-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4,5-二氟-2-甲氧基苄胺
• 英文名称: (4,5-difluoro-2-methoxyphenyl)methanamine
• 英文别名: 4,5-Difluoro-2-methoxybenzylamine
• CAS: 886497-93-4
• 化学式: C₈H₉F₂NO
• mdl: MFCD06660190
• 分子量: 173.162
• InChiKey: LZSNRJCSFRPZSW-UHFFFAOYSA-N

物化性质

• 沸点：
  219.5±35.0 °C(Predicted)
• 密度：
  1.220±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  8
• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  4,5-二氟-2-甲氧基苄胺 在 sodium hydride 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 为溶剂， 反应 1.17h， 生成 [4-(2-methylpropoxy)phenyl]methyl-N-[(4,5-difluoro-2-methoxyphenyl)methyl]-N-(1-methylpiperidin-4-yl)carbamate
  参考文献：
  名称：

  [EN] COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES
  [FR] COMPOSÉS, SELS ASSOCIÉS ET MÉTHODES DE TRAITEMENT DE MALADIES

  摘要：

  公开号：

  WO2019040104A3

文献信息

• [EN] COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES<br/>[FR] COMPOSÉS, SELS CORRESPONDANTS ET MÉTHODES POUR LE TRAITEMENT DE MALADIES
  申请人：ACADIA PHARM INC

  公开号：WO2019040107A1

  公开（公告）日：2019-02-28

  The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

  本公开涉及按照式（I）的化合物，用于治疗疾病。
• 8-Benzyltetrahydropyrazino[2,1-<i>f</i>]purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases
  作者：Andreas Brunschweiger、Pierre Koch、Miriam Schlenk、Felipe Pineda、Petra Küppers、Sonja Hinz、Meryem Köse、Stefan Ullrich、Jörg Hockemeyer、Michael Wiese、Jag Heer、Christa E. Müller

  DOI：10.1002/cmdc.201402082

  日期：2014.5.9

  designed as tricyclic xanthine derivatives containing a basic nitrogen atom in the tetrahydropyrazine ring to improve water solubility. A library of 69 derivatives was prepared and evaluated in radioligand binding studies at adenosine receptor (AR) subtypes and for their ability to inhibit monoamine oxidases (MAO). Potent dual‐target‐directed A1/A2A adenosine receptor antagonists were identified. Several

  8-苄基取代的四氢吡嗪并[ 2,1 - f ]嘌呤二酮被设计为在四氢吡嗪环中包含碱性氮原子的三环黄嘌呤衍生物，以提高水溶性。制备了69种衍生物的文库，并在放射性配体结合研究中评估了腺苷受体（AR）亚型及其抑制单胺氧化酶（MAO）的能力。确定了有效的双靶标定向A 1 / A 2A腺苷受体拮抗剂。几种化合物显示出三重靶标抑制作用。最好的化合物之一是8-（2,4-二氯-5-氟苄基）-1,3-二甲基-6,7,8,9-四氢吡嗪并[2,1 - f ]嘌呤-2,4（1 H，3 H）-dione（72）（人类AR：K i  A 1 217 n M，A 2A 233 n M；IC 50 MAO-B：508 n M）。二氯化化合物36 [8-（3,4-二氯苄基）-1,3-二甲基-6,7,8,9-四氢吡嗪并[2,1 - f ]嘌呤-2,4（1 H，3 H）-二酮]被认为是大鼠中最佳的三靶标药物（K i  A 1
• Structure-activity relationship and molecular modelling studies of quinazolinedione derivatives MMV665916 as potential antimalarial agent
  作者：Laura Mourot、Marjorie Schmitt、Elisabeth Mouray、Martin Spichty、Isabelle Florent、Sébastien Albrecht

  DOI：10.1016/j.bmc.2021.116513

  日期：2021.12

  MMV665916, which showed remarkable growth inhibition with EC50 value of 0.4 µM and presented the highest selectivity index (SI > 250). In addition, a novel approach for determining the docking poses of these quinazolinedione derivatives with their potential protein target, the P. falciparum farnesyltransferase PfFT, was investigated.

  一系列新的喹唑啉二酮衍生物很容易合成，并评估了它们的体外抗疟原虫生长抑制活性。大多数化合物在低至中等微摩尔浓度下抑制恶性疟原虫FcB1菌株。2-乙氧基8ag'、2-三氟甲氧基8ai'和4-氟-2-甲氧基8ak'显示出最好的抑制活性，EC 50值约为5 µM，并且对原代人成纤维细胞系AB943无毒。然而，这些化合物的效力不如最初的热门 MMV665916，后者显示出显着的 EC 50生长抑制作用值为 0.4 µM 并呈现最高的选择性指数 (SI > 250)。此外，研究了一种确定这些喹唑啉二酮衍生物与其潜在蛋白质靶标——恶性疟原虫法尼基转移酶Pf FT 的对接姿势的新方法。
• Compounds, salts thereof and methods for treatment of diseases
  申请人：ACADIA PHARMACEUTICALS INC.

  公开号：US11345693B2

  公开（公告）日：2022-05-31

  The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

  本公开涉及可用于治疗疾病的式 (I) 化合物。
• Truncated (N)-Methanocarba Nucleosides as A₁ Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition Element
  作者：Dilip K. Tosh、Khai Phan、Francesca Deflorian、Qiang Wei、Zhan-Guo Gao、Kenneth A. Jacobson

  DOI：10.1021/ml200114q

  日期：2011.8.11

  A(1) adenosine receptor (AR) agonists are neuroprotective, cardioprotective, and anxiolytic. (N)-Methanocarba adenine nucleosides designed to bind to human A(1)AR were truncated to eliminate 5'-CH2OH. This modification previously converted A(3)AR agonists into antagonists, but the comparable effect at A(1)AR is unknown. In comparison to ribosides, affinity at the A(1)AR was less well preserved than that at the A(3)AR, although a few derivatives were moderately A(1)AR selective, notably full agonist 21 (N-6-dicyclopropyl-methyl, K-i 47.9 nM). Thus, at the A(1)AR, recognition elements for nucleoside binding depend more on 5' region interactions, and in their absence, A(3)AR selectivity predominates. Based on the recently reported agonist-bound AR structure, this difference between subtypes likely correlates with an essential His residue in transmembrane domain 6 of A(1) but not A(3)AR The derivatives ranged from partial to full agonists in A(1)AR-mediated adenylate cyclase inhibition. Truncated derivatives have more druglike physical properties than other A(1)AR agonists; this approach is appealing for preclinical development.